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Abstract
Overexpression of the xenotoxin transporter P-glycoprotein (P-gp) represents one major reason for the development of
multidrug resistance (MDR), leading to the failure of antibiotic and cancer therapies. Inhibitors of P-gp have thus been
advocated as promising candidates for overcoming the problem of MDR. However, due to lack of a high-resolution
structure the concrete mode of interaction of both substrates and inhibitors is still not known. Therefore, structure-based
design studies have to rely on protein homology models. In order to identify binding hypotheses for propafenone-type P-
gp inhibitors, five different propafenone derivatives with known structure-activity relationship (SAR) pattern were docked
into homology models of the apo and the nucleotide-bound conformation of the transporter. To circumvent the
uncertainty of scoring functions, we exhaustively sampled the pose space and analyzed the poses by combining
information retrieved from SAR studies with common scaffold clustering. The results suggest propafenone binding at the
transmembrane helices 5, 6, 7 and 8 in both models, with the amino acid residue Y307 playing a crucial role. The identified
binding site in the non-energized state is overlapping with, but not identical to, known binding areas of cyclic P-gp
inhibitors and verapamil. These findings support the idea of several small binding sites forming one large binding cavity.
Furthermore, the binding hypotheses for both catalytic states were analyzed and showed only small differences in their
protein-ligand interaction fingerprints, which indicates only small movements of the ligand during the catalytic cycle.
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Introduction
The development of multidrug resistance (MDR) is one major
impediment in cancer and antibiotic therapies [1–3]. In 1976
Juliano and Ling were able to associate the occurrence of MDR
with the presence of P-glycoprotein (P-gp), the most prominent
member of the adenosine triphosphate (ATP) binding cassette
(ABC) transporter superfamily [4–6]. ABC proteins are energy
dependent transporters with P-gp (ABCB1), multidrug resistance
protein 1 (MRP1, ABCC1) and breast cancer resistance protein
(BCRP, ABCG2) playing an important role in the protection of
cells from harmful xenotoxins. Additionally, ABC proteins are
known for modulating the pharmacokinetic profile of drugs and
therefore the food and drug administration (FDA) suggested that
new drug candidates should be routinely screened for P-gp
interaction [7]. In this respect reliable in silico methods to
characterize P-gp interaction would be of great benefit and help
to render the drug discovery process more efficient [8]. However,
the polyspecificity of the transporter poses a remarkable challenge
concerning this task [9]. A number of ligand based studies have
been conducted and provide some insights into the molecular basis
of ligand/transporter interaction [10,11]. With the help of
biochemical studies like cysteine-cross linking, arginine scanning
or photoaffinity labeling, amino acids contributing to binding of
selected substrates were identified. On grounds of these experi-
ments interaction sites for verapamil, rhodamine (R-site), Hoechst
(H-site) and of cyclic peptide P-gp inhibitors (CPPI’s) in the
transmembrane (TM) domains (TMDs) of P-gp have been
postulated [12–16]. Following the ABC transporter topology, P-
gp possesses two TMDs, each consisting of 6 TM helices (TMHs),
and two nucleotide binding domains (NBDs). While the TMDs are
generally responsible for ligand interaction, ATP binding and
hydrolysis takes place at the highly conserved nucleotide binding
domains (NBDs) [17]. In case of propafenone type ligands
photoaffinity labeling studies proposed two symmetrical binding
regions at the interfaces of TMHs 5/8 and TMHs 2/11,
respectively [18,19]. Nevertheless, due to the small number and
the low resolution of crystal structures of ABC-exporters, concrete
binding hypotheses remain to be elucidated [20]. The lack of high
resolution structures can be explained by the fact that ABC efflux
pumps are located in the membrane and that they are rather
flexible proteins. As energy dependent transporters they undergo
large structural changes during one catalytic cycle, comprising
ligand and ATP binding, ligand release and nucleotide hydrolysis
[17,21,22]. Up to now the structure of human P-gp could not be
resolved, for which reason homology models relying on bacterial
homologues had to be utilized. With respect to this the bacterial
transporters Sav1866 and MsbA structures, representing different
catalytic states of the transport cycle, were generally used as
templates [20]. In 2009 the crystal structure of mouse P-gp [12] in
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a ligand binding competent conformation of the protein. With
88% sequence identity it is well suited for homology modeling of
the human homologue and thus paves the way for structure-based
approaches.
The present study aimed at elucidating the binding mode of
propafenone type inhibitors of P-gp using a combined homology
modeling/docking approach. Propafenones show a clear structure-
activity relationship (SAR) pattern [11] and thus represent versatile
tool compounds to pursue this task. The wealth of ligand-based
information available allows judging the reliability of docking poses
on basis of the SAR pattern rather than by use of energetic terms
derived from scoring functions. The selected compounds were the
piperidineanalogueGPV005, the analogous des-hydroxy derivative
GPV186, the arylpiperazine GPV019, the hydroxyphenylpiper-
idine GPV062, and the benzoylamide GPV366 (Figure 1). All
compounds bear a carbonyl group, which has been shown to be
important for high P-gp inhibitory activity [23].
There are numerous studies showing that there is a basic
underlying correlation between P-gp inhibitory activity and
lipophilicity of the compounds. This accounts for several
compound classes and has also been shown for propafenone
analogues.
However, propafenones which bear a 4-hydroxy-4-phenylpi-
peridine moiety are generally by a factor of 10 more active than
equi-lipophilic derivatives without the hydroxy-group in 4-position
of the piperidine moiety (Figure S1) [24]. This points at a distinct
additional interaction mediated by the 4-hydroxy group, most
probably in form of a H-bond. This distinct SAR pattern in
combination with the recently described common scaffold




In March 2009 Aller et al. published the crystal structure of
mouse P-gp in the absence of a ligand (PDB ID: 3G5U) [12] and
in complex with stereoisomeric CPPI’s (PDB IDs: 3G60, 3G61)
[12]. These structures represent the ligand binding competent
state and were therefore the first choices for investigating drug/P-
gp binding.
As the structural difference between the apo protein and the
co-crystallized structures was surprisingly low (0.61 A ˚ of Ca
atoms) the higher resolved 3G5U structure was utilized as
homology modeling template (3G5U_Pgp). With the modeling
program MODELLER 100 different homology models were
created and refined. All models were assessed with the geometry
check tool implemented in MOE, which was used as a selection
criterion for the final model. As additional measure for model
quality the GA341 method was used, which relies on sequence
identity, compactness and the combined statistical z-score. All
models obtained the highest possible GA341 value of 1.
Furthermore, the final model was analyzed with the structure
assessment program PROCHECK [27]. The Ramachandran
plot showed that 84.6% of the residues lie in most favored, 12.5%
in additionally allowed, 2.1% in generously allowed and 0.8% in
disallowed regions. The 2.9% of residues in generously allowed or
disallowed regions are located in the nucleotide binding domains
(NBD) or extracellular loops (ECL) and are therefore not involved
in drug binding (Figure S2). The QMEAN analysis [28] (Figure
S3) showed that residues lining the binding pocket are of
satisfactory quality.
In order to cover different catalytic states of the protein, a
second homology model was generated on basis of the bacterial
transporter Sav1866 in the nucleotide-bound state (PDB code:
2HYD) [29] (2HYD_Pgp). This crystal structure is the highest
resolution ABC exporter structure and has therefore been
frequently used as modeling template [20]. 100 different models
were generated and refined with MODELLER, of which all
obtained a GA341 score of 1. The final model was selected on
basis of the geometry check function in MOE. The Ramachan-
dran plot statistics provided by the evaluation tool PROCHECK
showed that 92% of all residues lie in most favored regions, while
6.5% were found in additionally allowed, 0.2% in generously
allowed and only 0.6% in disallowed regions (Figure S2). Most of
the 0.8% residues that are located in generously allowed or
disallowed regions can be found in the NDB. Although residue
Y116 lies within the TMDs and could therefore be involved in
drug binding, this residue is oriented outside the cavity. A
Ramachandran analysis performed by MolProbity and MOE
detected no outliers in the TM region. Furthermore, this model
shows also good quality in the binding site region according to
QMEAN analysis (Figure S3).
Docking
For the docking process five different propafenone derivatives
were selected according to their differences in lipophilic efficiency
and fit quality [30], and were docked into both homology models.
With the genetic algorithm based docking program GOLD [31]
100 poses for each of the five ligands were generated. To
determine the ASN, GLN and HIS flips the web application
MolProbity was utilized [32]. In order to avoid any bias, the
binding site was defined as the complete TM region. According to
the binding site assessment tool implemented in the software suite
Schro ¨dinger (SiteMap), this region in 3G5U_Pg mainly shows
highly hydrophobic characteristics, which prompted us to dock the
ligands in their non-ionized state. This is also supported by
previous findings of ligand-based QSAR studies which indicated
that the nitrogen atom not necessarily interacts in its charged
form. However, since there is evidence that the protein’s pore is
water filled, the ligands were also docked in their ionized state
[33]. This is also in accordance with recently published data which
show that mutation of two glutamine residues at the entry path of
Author Summary
A major reason for the failure of cancer, antibiotic and
antiviral therapies is the development of multidrug
resistance (MDR). P-glycoprotein (P-gp), an ATP-dependent
transport protein located in the membrane of epithelial
cells of the kidney, liver, pancreas, colon and the blood-
brain barrier, has been linked to the export of a broad
variety of xenotoxins. Overexpression of P-gp leads to
extrusion of therapeutic drugs and therefore triggers MDR.
Thus, identification of potential P-gp inhibitors represents
a promising concept for treatment of multiresistant
tumours. However, due to lack of high resolution structural
information and the polyspecific ligand recognition
pattern only very limited information is available on the
molecular basis of ligand/transporter interaction. Within
this study we characterized the propafenone binding site
of P-gp by docking a set of derivatives with known SAR
into homology models of P-gp which represent both the
apo and the nucleotide-bound state. Poses retrieved are in
accordance with results from previous photoaffinity
labeling studies and thus pave the way for structure-
based in silico screening approaches.
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PLoS Computational Biology | www.ploscompbiol.org 2 May 2011 | Volume 7 | Issue 5 | e1002036Figure 1. Ligand structures and codes that were used in this study. The common scaffold represents the largest common substructure and
was used for root mean square deviation (RMSD) clustering.
doi:10.1371/journal.pcbi.1002036.g001
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inhibitory activity of an positively ionizable propafenone analog,
whereas the activity of GPV366 remained unmodulated [34].
The resulting poses in both conformations were distributed
largely within the TM region of P-gp (Figure 2), showing
interactions with protein residues of multiple TM helices, located
throughout the binding region. The calculation of protein ligand
interaction fingerprints (PLIF) with MOE showed that in case of
3G5U_Pgp residues primarily located on TM helices 1, 5, 6, 7, 8,
11 and 12 were involved in binding (Figure 3). According to this
tool, residues involved either show direct interactions with docking
poses or are located within 4.5 A ˚ distance to the ligand.
The unprocessed complexes were energetically minimized using
LigX, a minimization tool implemented in MOE for further
evaluation.
The minimized poses were clustered according to the root-
mean-square deviation (RMSD) of the heavy atoms of the
common scaffold (Figure 1) [35]. To follow the idea of a common
binding mode only those clusters were kept that comprehend at
least four out of the five compounds used (common scaffold
clusters, CSCs). Clustering the poses of the docking run with
3G5U_Pgp resulted in 114 clusters, which were subsequently
reduced to 12 CSC. As can be seen in Figures 2a and b some
clusters protrude into the central cavity, but most of the CSCs are
found in the vicinity of helices 5 and 8 (called the 5/8 interface).
Previous photo-affinity labeling experiments suggested this region
to be in involved in propafenone binding [36]. The position of the
CSCs close to the 5/8 interface was also reflected in the PLIF
pattern, as the involvement of residues L304 and Y307 located in
TM helix 5, F343 of TM helix 6, L724 and I731 in TM helix 7,
A761 in TM helix 8 and V981 in TM helix 12 was increased
(Figure 3).
In case of 2HYD_Pgp, the RMSD clustering process resulted in
78 clusters, which were reduced to nine common scaffold clusters,
containing 264 poses (Table 1). As can be seen in Figure 2c and d,
also docking into the nucleotide-bound homology model results in
CSCs that tend to accumulate closer to the 5/8 interface and thus
in vicinity of the photo-affinity labeled residues (Figure S4). The
clustering process did not change the general PLIF pattern. TM
helices 5, 6, 7 and 8 show similar contributions before and after
scaffold clustering, but more frequently interactions were observed
with individual residues, like Y307 (TM helix 5), Y310 (TM helix
5), L724 (TM helix 7) and T769 (TM helix 8) (Figure 4).
The model based on the murine 3G5U structure represents the
binding competent state, whereas the model based on the
nucleotide-bound 2HYD structure likely represents the off-state
of P-gp ligands [37]. Since propafenones might show different
affinities towards these two structures, final pose evaluation was
carried out in different ways.
In the hit-to-lead decision process as well as in lead optimization
different efficiency metrics are applied to prioritise lead candidates.
Briefly, in case of equi-potent compounds these parameters select
for the smaller, more hydrophilic ones. As high lipophilicity
correlates with promiscuity, poor solubility and poor metabolic
clearance [38], candidates with high lipophilic efficiency (LLE =
log(potency) - logP) are preferred. Ligand based studies clearly
demonstrate a correlation between lipophilicity of P-gp inhibitors
and their biological activity. However, as P-gp is extracting its
ligands directly out of the membrane bilayer, this is most probably
a consequence of concentration in the membrane rather than of
direct protein interaction. Calculating the LLE normalizes for this
effect and aids in identifying ligands with increased activity as a
result of direct interaction with the protein rather than higher
biomembrane distribution. The 4-hydroxy-4-phenylpiperidine
GPV062 shows by far the highest LLE (Table 2) suggesting that
in contrast to the other ligands, the higher activity of GPV062 is
not due to a high logP value. While LLE normalizes for the
lipophilic bias in potency description, LE simply corrects for the
size of a molecule by dividing the activity of a compound by its
heavy atom count. This approach is extensively used in fragment
based drug design to select those fragments, which are worth being
further investigated. As Reynolds et al. [30] concluded that LE
generally is biased towards smaller molecules, the normalized size-
independent fit quality (FQ) was assessed. Both, LE and FQ,
clearly highlight the hydroxyphenylpiperidine GPV062 as being
the most efficient compound (Table 2). The explanation for the
increased LLE and FQ values seems to be the 4-hydroxy-group of
GPV062. As this group clearly reduces the lipophilicity of a
molecule, the increase in activity was interpreted as a result of
hydrogen bonding. Thus, those CSCs were prioritized in which
GPV062 is able to form a hydrogen bond between the hydroxyl-
group of the 4-hydroxy-4-phenyl moiety and the protein.
With 3G5U_Pgp only one quarter of all twelve common
scaffold clusters showed a hydrogen bond between the hydroxyl-
group of GPV062 and the protein (Table 1) (GPV062-OH
Clusters). These three clusters (CSCs I, II, III) are located very
close to each other at the 5/8 interface (Figure 5a), with an
increased number of interactions formed by residues L304, Y310,
L724, A761 and V981. Furthermore, the PLIF pattern showed
that interactions with TM helices 1 and 11 are no longer present.
The positions of CSCs I and III are very similar, since both are
forming a hydrogen bond with Y310 and a p/p-interaction with
F336. In CSC II, on the contrary, a hydrogen bond interaction
with A761 was observed.
For further evaluation of the poses a pharmacophore search was
performed, utilizing a model published by Langer et al. that based
on a set of propafenone type P-gp inhibitors [39]. Only those two
clusters that formed a hydrogen bond with Y310 matched this
pharmacophore query. As depicted in Figure 5b, both clusters
perfectly fit the photolabeling pattern observed in this half of the
protein.
Evaluation of the docking results with 2HYD_Pgp could not be
based on ligand affinity data, since this structure represents the
nucleotide-bound off-state and therefore is considered as the low-
affinity state for substrates. This rules out prioritization on basis of
SAR-information. All common scaffold clusters of 2HYD_Pgp are
in close vicinity of the 3G5U_Pgp GPV062-OH poses (Figure 6).
Discussion
Homology Modeling
The homology models generated in this study resemble two
different states of P-gp: the open-inward or apo state and the open-
outward or nucleotide-bound state. Since the publication of mouse
P-gp in the absence (PDB ID: 3G5U) or in complex with ligands
(PDB Ids: 3G60, 3G61) only a few homology models of the human
homologue were published on the basis of these structures. Pajeva
et al. presented two homology models that were based on the
structure of 3G61, chain A, which is complexed with QZ59-SSS
[40,41]. The advantage of selecting this template for homology
modeling is the presence of the complexed ligands. On the other
hand, 3G5U is resolved at higher resolution (3.80 A ˚) and shows
only minor differences in the binding site (RMSD of all atoms of
QZ59-SSS surrounding residues: 1.251 A ˚). However, the still
relatively low resolution of the template certainly needs to be taken
into account when it is used for docking experiments.
The open-outward model relied on the structure of the bacterial
homologue Sav1866 (PDB ID: 2HYD), which possesses the same
Binding Modes of Propafenone Type P-gp Inhibitors
PLoS Computational Biology | www.ploscompbiol.org 4 May 2011 | Volume 7 | Issue 5 | e1002036Figure 2. Distribution of all 500 poses in 3G5U_ _Pgp (A, B) and 2HYD_ _Pgp (C, D). Yellow: common scaffold cluster, grey: residual poses.
doi:10.1371/journal.pcbi.1002036.g002
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as modeling template. With a resolution of 3.0 A ˚ it represents one
of the best resolved full ABC transporters. The relevance of this
nucleotide-bound structure is widely accepted, as experimental
studies showed close association of the NBDs [43,44]. In contrast,
the structures of mouse P-gp disagree with kinetic and FRET
studies that report no complete dissociation of the NBDs [37,45].
In addition, a recent cross-linking study further strengthened this
by showing that an M1M cross-link between L175C and N820C
did not prevent verapamil and rhodamine B to be transported
[46]. However, as P-gp is known to be highly flexible and to
undergo large conformational changes during the catalytic cycle,
the existence of a state with dissociated NBDs cannot be ruled out
entirely. Additional evidence was presented by Sauna et al., who
demonstrated that ATP binding reduces the affinity for propafe-
none analogues [37]. Finally, the fact that the mouse P-gp
structure (3G5U) has been cocrystallized with two ligands strongly
indicates that this structure represents a ligand-binding competent
state of the protein. Thus it was considered as a versatile template
for modeling the high-affinity state of the protein for subsequent
docking studies.
Docking
Although ligand docking is a commonly used tool for the
identification of ligand-protein interactions, in case of P-gp it bears
a lot of challenges: (i) P-gp possesses a large binding cavity that
consists of several binding sites, (ii) is highly flexible, and (iii) is
probably able to harbor more than one ligand simultaneously
[47,48]. Finally, there is no high resolution structure of human P-
gp available, which requires to work with protein homology
models. Considering the low resolution of the templates, this adds
additional layers of uncertainty. Thus, results from ligand docking
runs have to be interpreted very carefully. In an attempt to combat
all these uncertainties we applied an exhaustive docking protocol
avoiding to a maximum possible extent the use of scoring functions
and including all the knowledge present from SAR and QSAR
studies.
In docking experiments, the definition of the binding site is a key
parameter of the docking protocol. As only little information is
available about binding of propafenones into P-gp, the whole TM
region was selected as a potential interaction region. In order to
avoid any bias introduced by scoring functions, a large amount of
docking poses was generated. While placement algorithms of
Figure 3. Protein ligand interaction fingerprint (PLIF) of the docking poses in 3G5U_ _Pgp, calculated with MOE. All: 500 poses after
docking, CSC: common scaffold cluster, GPV062: cluster that showed an interaction between the OH-group of GPV062 and the protein. Residues
marked with an asterisk show direct interaction with docking poses.
doi:10.1371/journal.pcbi.1002036.g003
Table 1. Cluster statistics of docking runs into different catalytic states.
3G5U_ _Pgp (non-ionized) 3G5U_ _Pgp (ionized) 2HYD_ _Pgp (non-ionized) 2HYD_ _Pgp (ionized)
Total number of poses 500 500 500 500
Number of clusters after RMSD clustering (3 A ˚) 114 111 78 77
Number of common scaffold clusters (CSCs) 12 (184 poses) 11 (195 poses) 9 (264 poses) 7 (240 poses)
CSCs with interaction between GPV062-OH
and protein
I, II, III IV, V, VI 22
ph4-matching clusters I, III IV, V, VI 22
doi:10.1371/journal.pcbi.1002036.t001
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of a ligand in the binding pocket, the correct estimation of the
binding energy leading to a correct ranking of the poses is still
unsatisfying. To overcome this uncertainty of scoring functions, we
recently implemented experimental data guided docking/scoring.
In this approach prioritization of docking poses is performed on
basis of mutagenesis data, biochemical data, and/or information
from ligand based studies [25,26].
The interaction of propafenones with P-gp follows a clear
structure-activity relationship pattern (for reviews see [11]). Based
on these results and on calculation of lipophilic efficiency (LLE)
and fit quality (FQ) we selected a small set of analogs for docking
and subsequent common scaffold clustering. Both LLE and FQ as
well as previously performed Hansch analysis stressed the
importance of the hydroxyl-group of GPV062 for high activity.
Clustering of all poses according to their common scaffold
(Figure 1) combined with pose selection based on H-bonding
interactions of the OH group allowed a considerable reduction of
docking poses.
Although docking experiments have their limitations depending
on the validity of the target structure, the results of docking into
3G5U_Pgp are very consistent. As shown in Figure 5 the three final
clusters are located in close vicinity. Especially CSCs I and III are
very similar, showing strong H-bonding interactions with Y310 and
thus supporting the importance of the hydroxyl group of GPV062.
Both clusters also match the pharmacophore model of Langer et. al
[39]. Due to previously performed ligand based studies also the
importance of the carbonyl group of the propafenone scaffold
became evident [49].Although initial poses showno interaction with
the carbonyl group, these become apparent after processing of data
with the rotamer explorer implemented in MOE. When rotating
amino acid residue Y307 towards the carbonyl group, an interaction
can be generated (Figure 7). In a dynamic system H-bond formation
thus might be observed. Interestingly, for CSC III a rotation of Y307
did not result in an interaction with the carbonyl group, most
probably due to a small offset of the carbonyl group towards the cell
interior. However, this assumption would need further investiga-
tions, since discussing possible interactions on atomistic detail has to
be done with caution when working with a homology model,
especially if the resolution is quite low. Nevertheless, the relevance of
Y307 in ligand binding was also shown with cocrystallized CPPI’s,
wherethe R-stereoisomerformsaninteraction withthisresidue [12].
Furthermore, this residue is in close vicinity to I306, which was
shown to lead to permanent activation of ATPase activity when
mutatedtocysteineandcovalentlylinkedwiththethiol-reactivedrug
substrate verapamil [15].
CSC II forms a weak H-bond between the hydroxyl-group of
GPV062 and the backbone of A761. With respect to the ligand
interaction tool in MOE the strength of this bond is only 1/10
compared to that in CSCs I and III. Applying the rotamer
explorer results in either formation of a stronger hydrogen bond
with the OH-group of GPV062 or formation of a new interaction
with the carbonyl group (with these interactions not being
coexistent). Finally, with respect to residues photoaffinity labelled
by benzophenone analogous propafenones, CSCs I and III show a
better match (Figure 5b), because the photoreactive carbonyl
group is closer to the PAL region than in CSC I.
Table 2. Activities of docked ligands.
Ligand pIC50 HAC ClogP LLE LE FQ
GPV005 6.22 27 4.38 1.84 0.23 0.77
GPV019 6.21 33 5.15 1.06 0.19 0.75
GPV062 7.24 34 4.15 3.09 0.21 0.87
GPV186 6.19 26 5.54 0.65 0.24 0.77
GPV366 5.78 33 4.94 0.84 0.18 0.70
HAC = heavy atom count, LLE = lipophilic ligand efficiency, LE = ligand
efficiency, FQ = fit quality.
doi:10.1371/journal.pcbi.1002036.t002
Figure 4. Protein ligand interaction fingerprint (PLIF) of the docking poses in 2HYD_ _Pgp, calculated with MOE. All: 500 poses after
docking, CSC: common scaffold cluster. Residues marked with an asterisk show direct interaction with the docking poses.
doi:10.1371/journal.pcbi.1002036.g004
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PLoS Computational Biology | www.ploscompbiol.org 7 May 2011 | Volume 7 | Issue 5 | e1002036Figure 5. GPV062-OH interaction clusters in the binding pocket of 3G5U_ _Pgp. CSC I (green), CSC II (yellow), CSC III (cyan). A) Top view; the
three interacting amino acids are colored according to their cluster-membership. B) side view; the blue surface indicates residues that are involvedi n
propafenone binding, determined by photoaffinity labeling [14].
doi:10.1371/journal.pcbi.1002036.g005
Figure 6. Comparison of docking poses in different stages of the catalytic cycle. Magenta: GPV062-OH clusters of docking into 3G5U_Pgp
(high affinity), green: common scaffold clusters of docking into 2HYD_Pgp (low affinity). A) overview, B) close-up view.
doi:10.1371/journal.pcbi.1002036.g006
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preferred over the other two clusters.
It is also known that binding of propafenones to P-gp meets
steric constraints in the vicinity of the nitrogen atom, because
diphenyl moieties in this position lead to a log order decrease in
activity [49]. In all three clusters the introduction of a diphenyl
substituted nitrogen results in steric clashes and subsequent
minimization of the binding pocket leads to the loss of H-bond
interactions.
Docking into 3G5U_Pgp with ionized ligands resulted in three
different CSCs that show an interaction between the OH_group of
GPV062 and the protein. While one is located very central in the
pore (CSC IV) forming an H-bond between GP062-OH and
A727, the other two (CSC V and VI) exactly match CSC I of the
docking with neutral ligands. For the latter an H-bond between
the hydroxyl-group and Y310 could be observed.
As can be seen in Figure 2, the different CSCs of 2HYD_Pgp
are located in the same binding site at the 5/8 interface.
Regarding their different orientation within this region, docking
poses can be separated into two distinct groups. Docking poses
belonging to group 1 (CSCs a, b, c and d) frequently form
interactions between the carbonyl group and Y307. Furthermore,
H-bond interactions between the piperidine nitrogen or the
hydroxyl-group and Y310 can be observed. This interaction
pattern is similar to the one of CSCs I and III of the docking run
performed with 3G5U_Pgp. Individual GPV062 poses show
additional H-bond interactions between the 4-hydroxy-group
and Y310, another frequently observed interaction in CSCs I
and III. According to these observations the transformation of
CSCs I and III in the apo state into CSCs of group 1 of the
nucleotide-bound state seems possible.
In contrast, group 1 and group 2 are in an up-side-down
orientation when compared to each other. In this case the
carbonyl group is located near Y310 and thus closer to the
extracellular portion of the protein. The nitrogen atom, as well as
the hydroxyl group, is oriented towards Y307 and N721, which
was also observed for CSC II of the 3G5U_Pgp docking run.
Therefore, group 2, comprising clusters e, f and g, corresponds to
the nucleotide-bound conformations of CSC II of the apo-
conformation.
CSCs h and i cannot be clearly assigned to one of these groups
and have to be regarded separately. The nitrogen atom of CSC h
shows a similar location as the N of group 2, however, due to a
shift of the central phenyl ring downwards, H-bond interactions
Figure 7. Interactions of CSC I with 3G5U_ _Pgp. By rotating the residue Y307 (grey:original, black: rotated) a new hydrogen bond between Y307
and the carbonyl group of the ligand was formed.
doi:10.1371/journal.pcbi.1002036.g007
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N721 can be formed simultaneously.
CSC i shares its carbonyl group orientation with group 2, but
the central phenyl ring lies in a perpendicular direction, which
results in interactions between the ligand nitrogen and hydroxyl
group with Q725.
Considering the docking run to 2HYD_Pgp with ionized ligands,
group 1 could be clearly reproduced. Three out of seven CSCs form
those characteristic H-bond interactions between the carbonyl
oxygen and Y307 and the hydroxyl group and Y310. In contrast to
the unprotonated ligands, the nitrogen atom and Y310 form a pi/
cation interaction and occur at higher frequency. Overall the
clusters belonging to group 1 show high homogeneity and strong
interactions. In contrast to this the poses of each of the four other
clusters share no consistent pattern and therefore the common
binding was only reflected in geometrically similar positioning.
Interestingly, although the experimental data suggest two
symmetrical binding sites, no common scaffold cluster and hardly
any poses could be found at the second photoaffinity labeled site at
the 2/11 interface. One possibleexplanation might be the asymmetry
of the template crystal structure 3G5U. The region consisting of TM
h e l i c e s4 ,5 ,7 ,8 ,9a n d1 2i nc a s eo f3 G 5 U _ P - g p ,a n dT Mh e l i c e s3 ,
4, 5, 6, 7 and 8 in case of 2HYD_P-gp, in both cases showed larger
sites when using the SiteFinder tool in MOE than their counterparts
around the 2/11 interface. This demonstrates the limitations of
docking experiments relying on one crystal structure that represents
only a snapshot of a flexible protein. Thus, to rule out the possibility
that every docked ligand will end up at the 5/8 interface just because
of this asymmetry, a docking run with rhodamine 123 was conducted.
In this case 21 of 39 clusters were found in vicinity of residues I340,
L975 and V981, which are located on TM helices 6 and 12 and
known to be involved in rhodamine binding [13].
Figure 8. Comparison of main interacting residues. The spheres represent Ca-atoms of interacting residues of 3G5U_Pgp (panels A, B) and
2HYD_Pgp (panels C, D). Blue spheres: 2HYD_Pgp, green: 2HYD_Pgp and 3G5U_Pgp, yellow: 3G5U_Pgp. A) and b) 3G5U_Pgp in front and top view; c)
and d) 2HYD_Pgp in front and top and view.
doi:10.1371/journal.pcbi.1002036.g008
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In order to gain first insights into the potential ligand
translocation pathways, the compounds were docked in two
different catalytic states of P-gp. Interestingly, the docking results
show similar interaction patterns. In both models, ligand poses are
found in close vicinity (4,5 A ˚) of residues Y307 and Y310 of TM
helix 5, F343 of TM helix 6 and L724 of TM helix 7, which
suggests involvement of both TM domains in drug binding. This is
in accordance with Loo et al., who showed that both TM domains
are essential for drug translocation [50].
In Figure 8 the interacting amino acid residues of both docking
approaches are depicted. In the 3G5U_Pgp structure the
interactions seem to be very similar, concentrating on the 5/8
interface. Due to the conformational change and the resulting
movement of TM helix 12, interactions between propafenones and
V977 and V981 are lost. Top views of the models indicate that the
corresponding interacting residues (3G5U_Pgp: yellow,
2HYD_Pgp: blue, both: green) face the central pore. It seems
that the conformational change associated with nucleotide binding
moves previously buried residues towards the binding pocket and
therefore allows them to form new interactions with the ligands.
In Figure 9 a Venn diagram compares residues in binding sites
of CPPIs and verapamil with that of propafenones. As TM helices
5, 6 and 7 are lining the central cavity in the murine P-gp
structure, a considerable overlap of residues interacting with
propafenones and that shown to interact with cocrystallized CPPIs
can be found in this region. One residue of TM helix 7, F728, is
suggested to interact with all four drugs and therefore plays a
crucial role in ligand binding. This is in agreement with the finding
of Loo et al. that TM helix 7 is part of the drug binding site [51].
Loo et al. also demonstrated that binding of vinblastine,
cyclosporin A and rhodamine B could prevent the formation of
a cross-link between L339C and F728C, suggesting that the
ligands are at least partially located between these two residues
[52]. This is also the case for the three docking clusters in
3G5U_Pgp, which are presented in this study.
Furthermore, the diagram is consistent with the notion that P-
gp possesses a large binding cavity, which harbors different
partially overlapping drug binding sites for different ligands
[39,40]. In the cocrystallized structures 3G60 and 3G61 the
cyclopeptides are located at the interface of the two TMDs, which
explains the high overlap between these ligands and verapamil or
propafenones, respectively.
Ligand docking into polyspecific antitargets such as the hERG
potassium channel and the drug transporter P-glycoprotein requires
thorough validation of the poses obtained. In this paper we describe
theapplicationofanSAR-guided docking protocol,whichfor thefirst
time retrieves a binding hypothesis for propafenone-type inhibitors of
P-gp. Although performing docking studies with homology models
always bears a lot of risks the results are in agreement with
experimental studies, which strengthens the applicability of the
complex docking protocol we used for this study. This could pave the
way for structure-based ligand design approaches.
Methods
Homology Modeling
Two homology models based on the bacterial homologue
Sav1866 (PDB ID: 2HYD, resolution: 3.0 A ˚ [29]) and murine P-
gp (PDB ID: 3G5U, chain A, resolution: 3.8 A ˚ [12]) were built.
Both models were generated with the program MODELLER 9v7
using the automodel protocol [53]. In case of 3G5U_Pgp the
alignment proposed by Aller et al. [8] was used (Figure S5). To
correct the disruption in TM helix 12 of 3G5U a secondary
structure constraint between residues 885 and 928 was applied.
For 2HYD_Pgp the alignment was done according to Stockner et
al. [54] (Figure S6). The linker region between the TM domains
was modeled. Out of the 100 generated models those with the
smallest number of outliers according to the geometry check
function in MOE were selected for docking.
Docking
For the docking study five propafenone derivatives were selected
on basis of known SAR and differences in LLE and FQ. LLE was
calculated by subtracting ClogP from experimentally determined
IC50 values and FQ was calculated as outlined in [30]. To examine
the quality of the ClogP calculation, the values were compared with
previously published experimentally defined logP data of propafe-
none analogs [23]. A correlation of r=0.92 could be identified.
Minimization and protonation of the ligands was performed
with MOE.
For the correct determination of ASN/GLN/HIS flips the web
application MolProbity was utilized [32]. The docking process was
performed using the Gold Suite 1.2.1 [31]. Hydrogens were added
and the binding site was defined as the entire TM region of the
homology model. All side chains were kept rigid and the ligand
Figure 9. Venn diagram of drug binding sites in human P-gp.
doi:10.1371/journal.pcbi.1002036.g009
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molecule. The implemented Gold scoring function GoldScore was
used for evaluation of the complexes. The final poses and the
surrounding protein amino acid residues were minimized using
LigX implemented in the MOE software package. Rescoring was
performed with the empirical scoring function XSCORE.
Cluster Analysis
On basis of the common scaffold an RMSD matrix of all five ligands
was generated and used for clustering. The dissimilarity matrix was
clustered with the program R [55], using complete linkage as clustering
algorithm and a clustering height of 3 A ˚. Only those clusters were kept
that inherited at least four out of the five ligands docked.
In case of 3G5U_Pgp those clusters were selected for final
assessment that were able to form a hydrogen bond between the
OH-group of GPV062 and the protein, detected by the ligand
interaction tool of MOE.
Supporting Information
Figure S1 ClogP-pIC50 correlation of propafenone
analogs. The ligands used for docking are highlighted. [24]
(TIF)
Figure S2 Outliers defined by PROCHECK analysis. A)
3G5U_Pgp, B) 2HYD_Pgp. Grey: generously allowed residues,
black: disallowed residues.
(TIFF)
Figure S3 QMEAN analysis of the homology models
generated with MODELLER. A) 3G5U_Pgp, B) 2HYD_Pgp.
Blue: high quality regions, red: low quality regions.
(TIFF)
Figure S4 Common scaffold clusters after docking into
2HYD_Pgp. The blue surface indicates residues that are involved
in propafenone binding, determined by photoaffinity labeling [14].
(TIFF)
Figure S5 Sequence alignment used for the generation
of the homology model 3G5U_Pgp. The sequences of human
P-gp and of the X-ray structure of mouse P-gp have been aligned
as suggested by Aller et al. [12].
(PDF)
Figure S6 Sequence alignment used for the generation
of the homology model of 2HYD_Pgp. The sequences of
human P-gp and the bacterial ABC-exporter SAV1866 have been
aligned as suggested by Stockner et al. [54].
(PDF)
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